Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02492334
Other study ID # 3733318
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date July 2016
Est. completion date December 16, 2019

Study information

Verified date December 2020
Source Medical University of South Carolina
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will test the efficacy of doxazosin, a long-acting and selective alpha-1 adrenergic antagonist, as compared to placebo in reducing PTSD symptomatology and alcohol use severity.


Description:

As a result of sustained operations in Afghanistan and Iraq, there are an increasing number of U.S. military personnel and Veterans at risk of developing both posttraumatic stress disorder (PTSD) and an alcohol use disorder (AUD). If left untreated, individuals with PTSD/AUD are at risk of developing other mental health problems (e.g., depression, anxiety), suicidal ideation and attempts, physical health problems, reduced resiliency, vocational problems, and family/relationship impairment. While mental health services are in place for U.S. military personnel and Veterans, there are substantial gaps in the evidence base to guide treatment of co-occurring PTSD/AUD. The proposed study directly addresses this gap by testing the efficacy of doxazosin, a long-acting and selective alpha-1 adrenergic antagonist, as compared to placebo in reducing PTSD symptomatology and alcohol use severity among U.S. military personnel (including National Guard and Reservists) who have served in Operation Enduring Freedom, Operation Iraqi Freedom, or Operation New Dawn (OEF/OIF/OND). The primary objectives of this stage II study are to evaluate the benefits of doxazosin as compared to placebo in reducing (1) PTSD symptomatology, (2) AUD severity, and (3) impairment in associated mental and behavioral health problems (e.g., depression, anxiety, sleep, risky behaviors) among OEF/OIF/OND Veterans (N=126) with co-occurring PTSD and AUD. Secondary objectives are to characterize the underlying pathophysiology of comorbid PTSD/AUD and identify prognostic indicators of treatment outcome using functional magnetic resonance imaging (fMRI). In order to accomplish this the investigators will (1) employ an intent-to-treat, double-blind, placebo-controlled randomized clinical trial that will consist of 12 weeks of treatment with doxazosin or placebo medication; (2) examine standardized, repeated dependent measures of clinical outcomes at 5 time points (baseline, week 4, week 8, week 12, and 1-month follow-up); and (3) employ advanced neuroimaging methodology.


Recruitment information / eligibility

Status Completed
Enrollment 144
Est. completion date December 16, 2019
Est. primary completion date November 13, 2019
Accepts healthy volunteers No
Gender All
Age group 21 Years to 65 Years
Eligibility Inclusion Criteria: 1. Male or female; any race or ethnicity; age 21 to 65 years old. 2. U.S. military veteran. 3. Score of > 21 on the Mini Mental Status Exam. 4. Subjects must be able to comprehend English. 5. Meet DSM-5 criteria for current (i.e., last 6 months) alcohol use disorder (AUD). 6. Meet DSM-5 criteria for current (i.e., last 6 months) PTSD. 7. Enrolled in the VAMC Substance Abuse Treatment Clinic (SATC) program. 8. Subjects taking psychotropic medications will be required to be maintained on a stable dose for at least eight weeks before treatment initiation. 9. Must consent to random assignment to doxazosin or placebo. 10. Must consent to complete all treatment and follow-up visits. 11. Must live within 50 miles of the Ralph H. Johnson VAMC in Charleston, SC. Exclusion Criteria: 1. DSM-5 criteria for a history of or current psychotic or bipolar affective disorders, current eating disorder, as the study protocol may be therapeutically insufficient. 2. DSM-5 criteria for another substance use disorder, except caffeine or nicotine, within the past 12 months. 3. Subjects experiencing significant withdrawal symptoms, as evidence by a score of 10 or above on the Clinical Institute Withdrawal Assessment of Alcohol (CIWA).These subject will be referred for clinical detoxification and may be re-assessed for study eligibility after medically supervised detoxification has been completed. 4. Individuals considered an immediate suicide risk based on the Columbia Suicide Severity rating Scale (C-SSRS) or who are likely to require hospitalization during the course of the study. 5. Previous treatment with doxazosin. 6. Subjects on maintenance anxiolytic, antidepressant, or mood stabilizing medications which have been initiated during the past four weeks. If it is determined, based on clinical criteria, that a subject needs to be started on maintenance medications for anxiety, mood or psychotic symptoms during the course of the study, they will be discontinued from the treatment trial. 7. Women who are pregnant, nursing or not practicing an effective form of birth control. 8. Individuals with a history of or current medical illness including unstable angina, myocardial infarction, congestive heart failure or other cardiac condition, hypotension or hypertension, renal or hepatic disorders, endocrine disorders, prostate or other cancer, pancreatitis, or a seizure disorder. 9. Subjects with abnormal liver function test (LFTs) as evidenced by laboratory findings of SGOT or SGPT greater than two times normal. 10. Subjects with a history of adverse reactions to quinazolines or other alpha-1-antagonists (such as allergic reactions, priapism, hepatitis, angioedema, or intraoperative floppy iris syndrome). 11. Individuals currently taking medications to treat hypertension, trazodone, hypnotics/benzodiazepines, mirtazapine, atypical antipsychotics, alpha-2-agonists, prazosin, conivaptan, boceprevir, fusidic acid, idelalisib, PDE-5 inhibitors or alpha-1-antagonists. 12. MRI exclusions: Claustrophobia; tattoos above shoulders; permanent eyeliner or eyebrows; cardiac pacemaker; metal fragments in eye, skin, or body, including shrapnel; heart valve replacement; brain clips; venous umbrella; being a sheet-metal worker or welder; history of aneurysm surgery; intracranial bypass, renal, or aortic clips; prosthetic devices such as middle ear, eye, joint, or penile implants; joint replacements; non-removable hearing aid, neurostimulator, or insulin pump; shunts/stents; metal mesh/coil implants; metal plate/pin/screws/wires; or any other metal implants.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Doxazosin
Doxazosin is a quinazoline compound that is a selective inhibitor of the alpha-1 subtype of alpha-adrenergic receptors. The chemical name is 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl) piperazine methanesulfonate. The molecular formula for doxazosin is C23H25N5O5 • CH4O3S and the molecular weight is 547.6. Doxazosin is used clinically to treat hypertension and improve urination in men with benign prostatic hyperplasia.
Placebo
Placebo, or inactive pill.

Locations

Country Name City State
United States Addiction Sciences Division-Medical University of South Carolina Charleston South Carolina

Sponsors (2)

Lead Sponsor Collaborator
Medical University of South Carolina Ralph H. Johnson VA Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary PTSD symptoms Clinician Administered PTSD Scale 12 weeks
Primary Alcohol use severity Time Line Follow Back 12 weeks
Secondary Characterize the underlying pathophysiology of comorbid PTSD/AUD and prognostic indicators of treatment responses fMRI Baseline
See also
  Status Clinical Trial Phase
Recruiting NCT04788004 - Long-term Recovery: Longitudinal Study of Neuro-behavioral Markers of Recovery and Precipitants of Relapse
Recruiting NCT05684094 - Mechanisms of Risky Alcohol Use in Young Adults: Linking Sleep to Reward- and Stress-Related Brain Function N/A
Completed NCT03406039 - Testing the Efficacy of an Online Integrated Treatment for Comorbid Alcohol Misuse and Emotional Problems N/A
Completed NCT03573167 - Mobile Phone-Based Motivational Interviewing in Kenya N/A
Completed NCT04817410 - ED Initiated Oral Naltrexone for AUD Phase 1
Active, not recruiting NCT04267692 - Harm Reduction Talking Circles for American Indians and Alaska Natives With Alcohol Use Disorders N/A
Completed NCT03872128 - The Role of Neuroactive Steroids in Stress, Alcohol Craving and Alcohol Use in Alcohol Use Disorders Phase 1
Completed NCT02989662 - INIA Stress and Chronic Alcohol Interactions: Glucocorticoid Antagonists in Heavy Drinkers Phase 1/Phase 2
Recruiting NCT06030154 - Amplification of Positivity for Alcohol Use N/A
Active, not recruiting NCT05419128 - Family-focused vs. Drinker-focused Smartphone Interventions to Reduce Drinking-related Consequences of COVID-19 N/A
Completed NCT04564807 - Testing an Online Insomnia Intervention N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT04203966 - Mental Health and Well-being of People Who Seek Help From Their Member of Parliament
Recruiting NCT05861843 - Craving Assessment in Patients With Alcohol Use Disorder Using Virtual Reality Exposure
Terminated NCT04404712 - FAAH Availability in Psychiatric Disorders: A PET Study Early Phase 1
Enrolling by invitation NCT04128761 - Decreasing the Temporal Window in Individuals With Alcohol Use Disorder N/A
Not yet recruiting NCT06337721 - Preventing Alcohol Use Disorders and Alcohol-Related Harms in Pacific Islander Young Adults N/A
Not yet recruiting NCT06444243 - Psilocybin-assisted Therapy for Alcohol Use Disorder Phase 2
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A
Enrolling by invitation NCT02544581 - Preliminary Analysis of the Soberlink Alcohol Breath Analyzer System's (SABA) Clinical Utility During Aftercare N/A